Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E2AF
|
|||
| Drug Name |
PMID27998201-Compound-2
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Patented | [1] | |
| Company |
MERCK FROSST CANADA LTD. GAUTHIER, Jacques-Yves TRUONG, Vouy-Lin
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin B (CTSB) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cathepsin B (CTSB) | Target's Patent Info | [1] | |
| KEGG Pathway | Lysosome | |||
| Antigen processing and presentation | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Reactome | Collagen degradation | |||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.